Immunome Stock Forecast
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:41 AM ET
IMNM analyst consensus
Consensus (16 analysts)
strong_buy
Avg. price target
$35.20+89.35%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 16 Wall Street analysts covering Immunome (2026-10-07), 15 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $35.20, with a high estimate of $40.00 and a low estimate of $24.00. The average target implies upside of 89.3% from the current price of $18.59.
The spread between the highest and lowest targets is 66.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IMNM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 19% |
| Buy | 12 | 75% |
| Hold | 1 | 6% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $24.00 | +29.10% |
| Average target | $35.20 | +89.35% |
| High target | $40.00 | +115.17% |